Related references
Note: Only part of the references are listed.Towards individualized follow-up in adult acute myeloid leukemia in remission
Peter Hokland et al.
BLOOD (2011)
Independent prognostic variables in acute myeloid leukaemia
Matthew L. Smith et al.
BLOOD REVIEWS (2011)
Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation
Yiming Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Kroenke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
M. R. Baer et al.
LEUKEMIA (2011)
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia
C. Craddock et al.
LEUKEMIA (2011)
Cytarabine Dose for Acute Myeloid Leukemia
Bob Löwenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
New agents in post-remission therapy
Richard M. Stone
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
The role of multiparameter flow cytometry for disease monitoring in AML
Wolfgang Kern et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy
Farhad Ravandi et al.
BLOOD (2010)
Adult Patients With Acute Myeloid Leukemia Who Achieve Complete Remission After 1 or 2 Cycles of Induction Have a Similar Prognosis A Report on 1980 Patients Registered to 6 Studies Conducted by the Eastern Cooperative Oncology Group
Jacob M. Rowe et al.
CANCER (2010)
Assessment of minimal residual disease in acute myeloid leukemia
David Grimwade et al.
CURRENT OPINION IN ONCOLOGY (2010)
Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
Michel Duval et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
Roland B. Walter et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Dario Campana
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2010)
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
Susanne Schnittger et al.
BLOOD (2009)
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
Daniela Cilloni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
David Grimwade et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Hugo F. Fernandez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob Lowenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2006)
High-dose cytosine arabinoside in the treatment of acute myeloid leukemia - Review of three randomized trials
Wolfgang Kern et al.
CANCER (2006)
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome
H Kantarjian et al.
CANCER (2006)
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia:: Results from cancer and leukemia group B study 8461
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome
HC Fung et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2003)
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML
EH Estey et al.
BLOOD (2003)
Share Paper
